For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaceutical company Pharmaxis (ASX: PXS) today announced positive interim results from the single ascending dose stage of the Phase 1 clinical trial for its Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor PXS4728A.
The single ascending dose stage was conducted in 48 healthy subjects divided into groups with each taking a single dose ranging from 1mg to 20mg or placebo. There were no safety concerns in patients receiving PXS4728A, and the Phase 1 study has now progressed into the multiple ascending dose stage where 24 subjects will be split into three groups and receive a dose of either active or placebo daily for 14 days. Three different dosages of PXS4728A will be trialled.
The single ascending dose stage of the trial also confirmed that PXS4728A is orally bioavailable and that after a single dose it produces long lasting inhibition of the SSAO/VAP-1 enzyme.Read full media release - pdf